IL2 and renal carcinoma: Renal cancer patients (n = 5) received subcutaneous 5-aza-2'-deoxycytidine daily x 5 days on weeks 1 and 2 of a 12-week cycle. High-dose IL-2, consisting of two cycles of IL-2 600,000 IU/kg intravenously every 8 hours' x 14 doses separated by a 2-week break, was administered starting on week 3. Decitabine was escalated from 0.1 to 0.25 mg/kg.